Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Wake Forest University Health Sciences
Primary Objective: To determine feasibility of telemedicine for outpatient cytokine release syndrome and neurotoxicity assessment (how many telemedicine visits successfully completed per patient)
Secondary Objective(s)
* To determine how many times a telemedicine visit triggered an action (inpatient admission/ outpatient observation status)
* To determine how many patients were detected to have cytokine release syndrome and/or neurotoxicity based on their telemedicine visit
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have histologically confirmed relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from of follicular lymphoma
Age ≥ 18 years
ECOG or Karnofsky performance status of ≤ 2
Patients must have a caregiver(s) with them 24 hours a day for the first 30 days after CAR-T cell infusion
Patients must stay within a 30-minute distance from the cancer center
Patients must have access to wifi network or a cellular network
Patients and caregiver(s) participating in patient's care must attend the education session for outpatient CAR-T and demonstrate competency to collect vital signs with equipment provided
Must have the ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).
You may not be if
Patients who have acute lymphoblastic leukemia/lymphoma
Patients who have a high tumor burden (\> 10 cm largest mass) have a high risk of CRS who will receive CAR-T as an inpatient
Patient or caregiver unable to understand and follow English language
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Clareo Health | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity
